Diagnosing & reversing the underlying pathology in the most debilitating systemic amyloid diseases
ATTR • AL • Other (e.g. ALECT2)
Our Novel Pan-Amyloid Targeting Pipeline
Potential to diagnose & reverse the underlying pathology of up to 30 systemic amyloid diseases
Novel Fc-fusion protein
Attralus is developing a novel Fc fusion protein that binds due to an undisclosed, but separate access point common to all amyloid fibrils. AT-03 utilizes a native protein armed with an Fc to stimulate the immune system which has the potential to results in clearance of amyloid.
Novel peptide-immunoglobulin fusion
Attralus is developing a novel peptide-immunoglobulin fusion in which an amyloid-reactive peptide (similar to AT-01) is fused to an Ig light chain (LC), which when associated with an Ig heavy chain (HC), yields a multi amyloid-reactive opsonin that can tightly bind and remove multiple forms of amyloid and stimulate immune activation of natural clearance mechanisms.
AT-02 has unique binding properties that enable a significantly higher avidity and accessibility to amyloid than typical antibodies. It does this by utilizing multiple binding sites (including fibrils and amyloid bound proteoglycans) that utilizes both charge and structure. AT-02 remains highly specific while enhancing phagocytosis of amyloid by macrophages.
Polybasic peptide radiotracer
Follow our AT-01 Clinical Trial at ClinicalTrials.gov
Attralus has developed a synthetic, novel, peptide radiotracer – AT-01 (¹²⁴I-p5+14) - that binds to many forms of amyloid, including AL, ATTR, and ALECT2. It is composed of an iodine-124 labeled peptide p5+14 and may be utilized for diagnostics, patient selection, staging, and disease/treatment monitoring purposes. PET/CT imaging using this radio tracer may provide a rapid, first-line diagnostic reagent for quantitative monitoring of response to therapy in patients with diverse forms of systemic amyloidosis.
The first-in-man, Phase 1/2, study of AT-01 for PET/CT imaging of 88 patients with systemic amyloidosis is currently underway (NCT03678259). Initial image data show AT-01 is capable of detecting:
- AL amyloid in the heart, kidney, liver, spleen, lung, adrenal gland, and pancreas
- TTR amyloid in the heart, nerves, lung, and connective tissue in hands and spine
- ALECT2 amyloid in the kidneys, liver, spleen, and adrenal gland
- Pre-Symptomatic cardiac disease in AL and ATTR
Proprietary pan-amyloid targeting agents to transform diagnosis & treatment
A New Path Forward
Our technology leverages proprietary pan-amyloid targeting agents with the potential to diagnose and treat all forms and stages of systemic amyloidosis. Attralus is focused on targeting the underlying pathology in all systemic amyloid diseases, with the goal of developing potential treatments for many subtypes of amyloidosis.
In contrast to current treatments, which reduce the formation of new amyloid fibrils and slow disease progression but do not address already deposited amyloid, Attralus is developing novel pan-amyloid targeting agents to directly bind and remove toxic amyloid fibrils from organs and tissues throughout the body, with the potential to reverse disease pathology. Unlike current monoclonal antibodies in development for systemic amyloidosis, Attralus’s therapeutics target motifs that are universally and ubiquitously presented on all amyloid fibrils. This pan-amyloid binding profile allows Attralus’s therapeutics to target multiple types of amyloid fibrils including AL, ATTR, ALECT2 and others.
Phase 1 data for our imaging agent, AT-01, show excellent binding and imaging properties for the three most common systemic amyloid diseases —ATTR (transthyretin), AL (light chain), and ALECT2 amyloidosis—as well as other rarer forms.
Selected images of systemic amyloidosis patients imaged with AT-01
Examples of Images for Ph 1/2 trial of AT-01 in ATTR, AL and ALECT2 patients
TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION
Please view on a desktop or laptop computer.